Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:17:27 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ADAP - ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS - http://www.adaptimmune.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ADAP - Q0.81.05·1.070.21.05+0.151616.9981.39559640.9499  1.08  0.922.05  0.4211:57:01Apr 1215 min RT 2¢

Recent Trades - Last 10 of 964
Time ETExPriceChangeVolume
11:57:01Q1.050.151615
11:57:01Q1.050.151612,991
11:56:55Q1.05010.1517250
11:56:40Q1.05890.160560
11:56:34Q1.060.16161,400
11:56:34Q1.0610.1626300
11:56:34Q1.060.1616100
11:56:34Q1.060.1616200
11:56:34Q1.0610.1626500
11:56:34Q1.0610.1626300

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-12 08:01U:ADAPNews ReleaseStrategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
2024-03-27 19:31U:ADAPNews ReleaseResults of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
2024-03-06 07:01U:ADAPNews ReleaseAdaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
2024-02-27 08:02U:ADAPNews ReleaseAdaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
2024-02-21 16:02U:ADAPNews ReleaseAdaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
2024-01-31 16:45U:ADAPNews ReleaseAdaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
2024-01-04 07:38U:ADAPNews ReleaseAdaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
2023-12-06 07:01U:ADAPNews ReleaseAdaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
2023-11-29 08:01U:ADAPNews ReleaseAdaptimmune Receives Transfer of IND for Lete-cel Program
2023-11-08 07:31U:ADAPNews ReleaseAdaptimmune Reports Third Quarter Financial Results and Business Update
2023-11-08 07:06U:ADAPNews ReleaseAdaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
2023-10-31 08:01U:ADAPNews ReleaseAdaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
2023-10-31 08:01U:ADAPNews ReleaseAdaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
2023-10-25 08:07U:ADAPNews ReleaseAdaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
2023-10-23 04:16U:ADAPNews ReleaseNext-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
2023-09-11 08:01U:ADAPNews ReleaseDr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
2023-08-09 07:30U:ADAPNews ReleaseAdaptimmune Reports Second Quarter Financial Results and Business Update
2023-08-03 13:25U:ADAPNews ReleaseAdaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
2023-06-01 15:30U:ADAPNews ReleaseAdaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
2023-05-25 17:01U:ADAPNews ReleaseAdaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO